Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report

作者：Liang, Yi-Chen; Wu, Gang; Cheng, Jing; Yu, Dan-Dan; Wu, Hong-Ge^*

来源：Oncology Letters, 2015, 10(3): 1277-1280.

DOI：10.3892/ol.2015.3463

• advanced non-small cell lung cancer
• gefitinib
• intestinal obstruction

Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib-induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies.

• 出版日期2015-9
• 单位华中科技大学